ACW
Director Trades
| Date | Director | Value |
|---|---|---|
| 3/11/24 | G. Brooke | $50,000 |
| 3/11/24 | S. Gourlay | $1,000,000 |
| 3/11/24 | G. Morstyn | $50,000 |
| 3/11/24 | M. McComas | $30,000 |
Company News
Actinogen Medical’s Xanamem shows promising results in depression treatment trials
Australian biotechnology company Actinogen Medical (ASX: ACW) has received further positive analysis from studies of its Xanamem treatment for symptoms of depression. The consistent benefits observed in the XanaCIDD phase 2a depression trial data support the conclusion that a 10 milligram Xanamem dose is clinically active in controlling brain cortisol and has clinically-significant anti-depressant activity. […]
Market wrap: inflation pushes share prices lower on last trading day of the financial year
Inflation was the word on everybody’s lips as they dumped shares on the last trading day of the financial year but it was the price of goods and services rather than shares that had caught their attention. The week’s stunning news that inflation had reared back up to 4% for the year to May brought […]
Actinogen’s Xanamem could slow Alzheimer’s progress, new biomarker trial reveals
A biomarker trial of Actinogen Medical’s (ASX: ACW) lead candidate Xanamem has been published in the peer-reviewed Journal of Alzheimer’s Disease, with results showing the drug has the potential to slow disease progression in patients with elevated levels of phosphorylated tau (pTau). The trial comprised 72 participants from Actinogen’s previous XanADu Phase 2a trial who […]
Actinogen Medical launches Alzheimer’s trial to test impact of Xanamem on cognitive health
Actinogen Medical (ASX: ACW) has treated the first subject in its clinical trial of patients with biomarker-positive mild to moderate Alzheimer’s disease. The XanaMIA Phase 2b trial involves 220 participants with elevated levels of the blood biomarker pTau and measures the effects of a Xanamem 10mg daily dose versus placebo over a 36-week treatment period. […]
Actinogen Medical announces ‘breakthrough’ study results for Alzheimer’s drug Xanamem
Actinogen Medical (ASX: ACW) has announced “breakthrough” results from its XanaHES higher dose safety study first initiated last year. The results reaffirm the foundational hypothesis that reducing cortisol levels can improve cognition with the pivotal factor being dosage. Moreover, the company announced that its trial results “exceeded expectations” and could result in Xanamem being utilised […]
Actinogen Medical phase two Alzheimer’s clinical trial disappoints
Biotech company Actinogen Medical (ASX: ACW) has reported a mixed bag of results including some disappointing outcomes from its XanADu phase two clinical trial treating patients with mild dementia due to Alzheimer’s disease. According to initial data released today, the trial established that a 10mg daily dose of Xanamem is safe and can effectively inhibit […]
Actinogen Medical attracts US biotech investor as Alzheimer’s XanADu study remains on track
Actinogen Medical (ASX: ACW) has received a double-shot of positive news earlier today after the biotech company received the all-clear from the Data Safety and Monitoring Board (DSMB) to continue its landmark phase 2 XanADu study, in addition to welcoming a new cornerstone investor onto its shareholder register, as part of a $15 million capital injection from […]
Actinogen moves towards XanADu starting line to treat Alzheimer’s disease
Biotech company Actinogen Medical (ASX: ACW) has confirmed that it has obtained half of the required patients in order to conduct its landmark Phase 2 clinical trial of Xanamem, a drug candidate to treat Alzheimer’s disease. Actinogen said that a total of 87 patients have been enrolled into XanADu, representing half of the total 174 […]
